Psychedelic therapies developer and provider Field Trip Health Ltd. (TSX:FTRP) (NASDAQ:FTRP) reported fiscal fourth quarter and full year 2022 results for the period ended March 31, 2022 and completed a strategic review resulting in the intention to separate the Field Trip Discovery and Field Trip Health divisions into two independent public companies.
The company’s Discovery division leads the development of next-gen psychedelic molecules and conducts research on plant-based psychedelics, and the Health division runs centers for psychedelic therapies across North America and Europe.
